Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation® Canada

Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long COVID.

20 reasons to give the gift of hope this year!

Last chance to donate in 2020!

As we come to the end of 2020, Open Medicine Foundation Canada (OMFCA) wishes you and yours a peaceful New Year’s. Thanks to the generosity of our community, we remain hopeful for a promising 2021.

It’s not too late to join our community of supporters and make your 2020 year-end contribution to OMFCA!

Make your donation before midnight, December 31!

All gifts large and small made to OMFCA help accelerate critical research. Our five OMF funded collaborative research centers are conducting over 20 — you read that right, 20! — studies and trials to help find diagnostics, treatments and a cure for millions suffering from ME/CFS, Post-treatment Lyme Disease, and related chronic, complex diseases:

Major Funded Research Initiatives

Severely Ill Patient Study

Metabolic Trap Study

Nanoneedle Diagnostic Tool

Red Cell Deformability and Blood Flow Study

T-Cell and Immunology Study

PASS/CAT: Artificial Intelligence (AI) Diagnostic Tool

Skeletal Muscle Study

Multi-omics Exercise Intolerance Study

Neuro inflammation Study

Mestinon Clinical Trial

Autoimmunity and Autoantibody Study

Kynurenine Clinical Trial

Post-viral Encephalopathy study

Multi-omics Study

Thrombospondin-1 (TSP-1) Study

Stress-Activated MicroRNAs Study

Nitrogen Hypothesis Study

And with COVID-19 top of mind, we are funding a
Post COVID-19 to ME/CFS Research Study:

The current COVID-19 pandemic offers an unprecedented opportunity to understand how a viral infection may convert to ME/CFS in some patients. The five ME/CFS Collaborative Centers have begun a unique, extensive, in-depth longitudinal molecular study following COVID-19 patients to determine the pathways involved in the maintenance of long-term symptoms in some patients, possibly converting to ME/CFS. They seek to learn about these pathways to develop biomarkers, novel drug targets, and new treatment and prevention strategies.

This is your last chance in 2020 to give the gift of hope
and invest in groundbreaking research
—  Please donate to OMFCA today